For over 40 years, sodium selenite has been recognized as a selective chemotherapeutic agent. Sodium Selenite is an inorganic form of selenium that has been shown in numerous in vitro, in vivo and human clinical studies to trigger apoptosis universally in all forms of cancer. Sodium Selenite is a small water soluble molecule and there is a natural high uptake into tumor tissue. Excesses of any form of selenium can be toxic but there is a very safe dosage range where sodium selenite can treat cancer without any adverse side effects or toxicity. Administration of sodium selenite can be sublingual, swallowed or by IV injection. Typical therapeutic dosage is in the range of 10-30 mg per day. NORI Nutraceuticals has developed various forms of sodium selenite tablets and liquids for therapeutic use. Sodium Selenite is classified as a pro-oxidant and offers synergy with other pro-oxidants and chemotherapy agents. One may ask why Sodium Selenite has not been developed as a drug and the answer is that it is not patentable in its natural form. Rather than developing Sodium Selenite as a drug, it can be developed as a nutraceutical product to be incorporated within an integrative oncology setting. Of all the natural compounds studied for their anti-cancer effects, Sodium Selenite stands out as the most potent agent. The properties of Sodium Selenite such as solubility, bioavailability, biocompatibility, pharmacokinetics, low-toxicity, selectivity and low-cost make it an ideal agent for the treatment of cancer.